Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Abstract

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.).

Keywords

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineVirologyBetacoronavirusInternal medicineInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel , Kay M Tomashek , Lori E. Dodd +37 more

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory trac...

2020 New England Journal of Medicine 7559 citations

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Wei-Jie Guan , Wenhua Liang , Yi Zhao +44 more

Background The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. Objective To evaluate the risk of serious adverse outcomes in patients with COVID-19 b...

2020 European Respiratory Journal 3724 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

Clinical Characteristics of Coronavirus Disease 2019 in China

Wei‐jie Guan , Zhengyi Ni , Yu Hu +34 more

BACKGROUND: Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical charac...

2020 New England Journal of Medicine 30728 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Publication Info

Year: 2020
Type: article
Volume: 384
Issue: 9
Pages: 795-807
Citations: 1863
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1863

OpenAlex

Cite This

APA Style

                            
                                
                                    André C. Kalil, 
                                
                                    Thomas F. Patterson, 
                                
                                    Aneesh K. Mehta
                                
                                et al.
                            
                            (2020). 
                            Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. 
                            New England Journal of Medicine
                            , 384
                            (9)
                            , 795-807.
                            https://doi.org/10.1056/nejmoa2031994
                        

Identifiers

DOI: 10.1056/nejmoa2031994